Rod Ellis MD

Professor & Vice-Chair USF and TGH Department of Radiation Oncology.Genito-Urinary Radiation Oncologist. PI NRG GU005 and NCI Co-Chair Renal Task Force

[Rod Ellis MD @ellis_rod]

@SbrtSean @blally_md @ACRORadOnc That is why James and I developed the SUGAR trial. Same cohort we used in GU-005 but if Decipher >4 using Regulolix for 1 month with SBRT starting week 2. Opens soon at USF/TGH!

[Rod Ellis MD @ellis_rod]

@SbrtSean Is it as good as it sounds?

[Rod Ellis MD @ellis_rod]

@officialKeef After last seeing the Rolling Stones in CLE 22 years ago it was great to see them back here again. Covid cancelled my last chance to see them 2years ago, but it was great to see Keef and Mick rock and rolling along with the rest of the band. What a show!

[Rod Ellis MD @ellis_rod]

@MSteinbergMD @AmarUKishan @UCLAHealth @dgsomucla @UCLAHealthNews Congratulations Amar!

[Rod Ellis MD @ellis_rod]

@PervinHurmuz It is good to see these data supporting pelvic radiotherapy in node positive men. So much more ommoninthis PSMA era.

[Pervin Hurmuz @PervinHurmuz]

👀Check out our new paper about the role of definitive RT for cN+ Prostate Cancer
Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Rad… https://t.co/ikl5YP2Gh6

[Rod Ellis MD @ellis_rod]

@SbrtSean @USF @tgh We are all so excited to welcome you at USF and TGH! Go Bulls!

[Rod Ellis MD @ellis_rod]

@SbrtSean Interesting finding, maybe a secondary analysis of Pace B or on my NRG GU-005 trial in the future would add numbers to evaluate this hypothesis.

[Rod Ellis MD @ellis_rod]

@SbrtSean The low toxicity and significant response in retreating is impressive!

[Rod Ellis MD @ellis_rod]

@sbrtmemes Piece of cake, I’ve done it twice already

[Rod Ellis MD @ellis_rod]

@SbrtSean Great choice! Love that place.

[Rod Ellis MD @ellis_rod]

@TallAllen @SbrtSean Based on 0815 I’d consider 4 months Orgovyx. If his Decipher was high risk SUGAR trial is offering 1 month Orgovyx with SBRT. I will be offering at USF/Tampa General. If he declined HT 8Gy x5 rather than 36.25 Gy or use a SIB of 40 Gy to bulky disease

[Fabio Arcidiacono @FabArcidiacono8]

Congrats @_ShankarSiva &Team
📢Excellent results FASTRACK II phase II trial.#SAbR effective and safe for primary kidney cancer💪🏻Median Tsize 4.6cm.26Gy/SF(33%) 42Gy/3F(67%).Median FU43m,LC & cancer-specific surv💯% 3-y distant-failureFS 97%.Moving FAST to R phase III trial 🔪⚔️☢️

[Rod Ellis MD @ellis_rod]

@FabArcidiacono8 @_ShankarSiva @TROGfightcancer @TheLancetOncol @PeterMacRadOnc Great data, good to see international growth of renal SBRT trials. Look forward to the phase III results!

[Rod Ellis MD @ellis_rod]

@SbrtSean The data are encouraging. Less toxicity than LDR/HDR and competed in 28 fractions. ROCR could remove the outdated codes disallowing SBRT reimbursement with an IMRT course. In time newer NRG GU series may show 5 fx SBRT alone works using SIB 5/7.25/8 Gy +/- dominate lesion boost

[Rod Ellis MD @ellis_rod]

@wallyjc Congrats Wally! I can’t wait to see what your leadership brings to the new Oncology role you’re starting on the 9th. Best wishes.

[Rod Ellis MD @ellis_rod]

@drmattmc Yep! Those moments with students are second only to the interaction with my patients! Teaching is always at the heart of it all.

[Rod Ellis MD @ellis_rod]

@DrSpratticus @ParikhSimul @DrAndrewLoblaw @rtdess @UH Sadly it’s fair to sad no randomized trials confirm a Brachy benefit. Maybe RTOG 0815 or 0924 secondary analysis might see a signal?

[Rod Ellis MD @ellis_rod]

@DrSpratticus @ParikhSimul @DrAndrewLoblaw @rtdess My data from series @UH Case shows great 10yr bDFS and improved DSS using Brachy/beam or Brachy alone in PSMA bases Capromab SPECT staging for localized disease 99 vs 86% in >240 consecutive pts. UCLA data shows 89% MFS Beam/Brachy vs 66 Beam/HT vs 60 Surg in high grade Gleason.

[Michael Chuong @MikeChuongMD]

Despite the debate around #MRgRT its impact on #radonc is undeniable. The inability for sites to continue using #MRIdian still seems like a bad dream. But it will soon become reality and patients w/o question are those who immensely lose. What a complete and utter shame.